Plain-English translation of NCT06427330 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing , a targeted cancer drug, in patients with acute lymphoblastic leukemia (a blood cancer) who have already undergone a stem cell transplant. The trial is designed to see whether this medication can prevent the disease from returning in patients whose leukemia is considered high-risk. Researchers will measure how well the medication works and track any side effects.
Even after a successful stem cell transplant, some patients with acute lymphoblastic leukemia face a high risk that their cancer will come back. Doctors need better ways to prevent relapse in these high-risk patients, and this trial is testing whether this medication—which targets specific cancer cells—could improve survival and reduce the chance of the disease returning.
If you join this trial, you will receive the medication in two doses at your study visits. You will continue receiving the medication until your leukemia comes back, you experience unacceptable side effects, or for as long as the study protocol requires. Throughout the trial, you will have regular follow-up appointments where doctors will monitor your blood counts, check how you're doing, and watch for any side effects. The main goal is to measure whether you remain disease-free at one year after starting treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~21 participants
Started
July 2024
Primary completion
June 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.